Bone remodeling is a process by which old bone is resorbed and formed, resulting in the replacement of approximately 10% of the skeleton every year. If the balance between bone resorption and bone formation is affected, the rate at which each process takes place changes which can have a large impact on the remodeling of the bones. This imbalance may result in weak, brittle or deformities of affected bones.
Changes in the rate at which bone is formed and resorbed can be measured by the evaluation of specific markers of bone turnover. Bone Alkaline Phosphatase (BAP) and Osteocalcin are considered markers of bone formation while Type I collagen telopeptides (NTx and CTx) are released during bone resorption.
The LIAISON® Osteocalcin assay is a one-step sandwhich chemiluminescence immunoassay (CLIA) intended for the quantitative determination of osteocalcin in human serum. Assay results should be used in conjunction with other clinical and laboratory data to assist in the diagnosis of postmenopausal osteoporosis and in the management of conditions involving an excess or deficiency of osteocalcin. This assay is intended for in vitro diagnostic use.
The DiaSorin LIAISON® BAP OSTASE® assay is a one step delayed addition sandwich chemiluminescence immunoassay (CLIA) intended for the quantitative determination of Bone Alkaline Phosphatase (BAP) in human serum. This device is intended to be used as an aid in the management of osteoporosis and Paget’s disease. The test has to be performed on the LIAISON® Analyzer family.
